on DocMorris AG (isin : CH0042615283)
DocMorris Reports 6.7% Growth in 2024 with Strong Rx Revenue Surge
DocMorris AG announced a 6.7% growth in revenue for 2024, reaching CHF 1,085 million. Growth was driven across all divisions, with notable success in the Rx segment. Rx revenue soared by 16.6% in Q4 and the number of new Rx customers increased fivefold. OTC revenues also matched overall growth at 6.7%.
In Germany, key market revenue rose by 6.9%, totaling CHF 1,021.9 million. This was complemented by significant Rx customer activity and a strong performance by TeleClinic, which doubled its revenue to approximately CHF 11 million. The Europe segment, focusing on Spain, France, and Portugal, saw a 3.6% revenue increase.
Despite challenges, the company attained a cash position of CHF 95 million by year-end, alongside the successful execution of its break-even programme and strategic streamlining initiatives.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DocMorris AG news